Publications en collaboration avec des chercheurs de University of Cologne (26)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  4. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study

    Nature Medicine, Vol. 30, Núm. 7, pp. 2020-2029

  5. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2022

  1. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    Leukemia, Vol. 36, Núm. 5, pp. 1371-1376

  2. TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: An international performance evaluation study

    Journal of Clinical Pathology, Vol. 75, Núm. 6, pp. 416-421

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962

  2. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial

    Leukemia, Vol. 34, Núm. 7, pp. 1760-1774

2019

  1. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: Results from 3 UK clinical trials

    Blood Advances, Vol. 3, Núm. 16, pp. 2474-2481

  2. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens

    Cancer Cytopathology, Vol. 127, Núm. 5, pp. 285-296

2017

  1. Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis (European Journal of Nuclear Medicine and Molecular Imaging, (2017), 44, 3, (353-357), 10.1007/s00259-016-3589-9)

    European Journal of Nuclear Medicine and Molecular Imaging

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  3. Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists

    World Neurosurgery, Vol. 99, pp. 41-46

  4. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis

    European Journal of Nuclear Medicine and Molecular Imaging

  5. The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy

    NeuroImage: Clinical, Vol. 13, pp. 386-394

2016

  1. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

    Neuro-Oncology, Vol. 18, Núm. 9, pp. 1199-1208

2015

  1. A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives

    European Journal of Nuclear Medicine and Molecular Imaging